ES2059547T3 - Expresion y secrecion mejoradas de proteinas heterologas en levadura, empleando secuencia conductora de factor alfa truncado. - Google Patents

Expresion y secrecion mejoradas de proteinas heterologas en levadura, empleando secuencia conductora de factor alfa truncado.

Info

Publication number
ES2059547T3
ES2059547T3 ES88312306T ES88312306T ES2059547T3 ES 2059547 T3 ES2059547 T3 ES 2059547T3 ES 88312306 T ES88312306 T ES 88312306T ES 88312306 T ES88312306 T ES 88312306T ES 2059547 T3 ES2059547 T3 ES 2059547T3
Authority
ES
Spain
Prior art keywords
yeast
secretion
alpha factor
improved expression
truncated alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88312306T
Other languages
English (en)
Inventor
Patricia Tekamp-Olson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ES2059547T3 publication Critical patent/ES2059547T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A UN SISTEMA DE EXPRESION DE FACTOR QUE CONTIENE EL PEPTIDO SEÑAL DEL FACTOR ALFA Y UN SITIO DE GLICOSILACION, UNIDO POR UN SITIO DE TRATAMIENTO A UNA SECUENCIA CODIFICADORA DE UNA PROTEINA QUE NO ES DE LEVADURA.
ES88312306T 1987-12-30 1988-12-23 Expresion y secrecion mejoradas de proteinas heterologas en levadura, empleando secuencia conductora de factor alfa truncado. Expired - Lifetime ES2059547T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13968287A 1987-12-30 1987-12-30

Publications (1)

Publication Number Publication Date
ES2059547T3 true ES2059547T3 (es) 1994-11-16

Family

ID=22487825

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88312306T Expired - Lifetime ES2059547T3 (es) 1987-12-30 1988-12-23 Expresion y secrecion mejoradas de proteinas heterologas en levadura, empleando secuencia conductora de factor alfa truncado.

Country Status (15)

Country Link
US (2) US5602034A (es)
EP (1) EP0324274B1 (es)
JP (1) JP2793215B2 (es)
AT (1) ATE97441T1 (es)
AU (1) AU616228B2 (es)
CA (1) CA1340772C (es)
DE (1) DE3885728T2 (es)
DK (2) DK175910B1 (es)
ES (1) ES2059547T3 (es)
FI (1) FI100995B (es)
HK (1) HK139994A (es)
IE (1) IE62087B1 (es)
IL (1) IL88802A0 (es)
NO (1) NO178829C (es)
PT (1) PT89367B (es)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5170964A (ja) * 1974-12-16 1976-06-19 Hohnen Oil Haisuinoshoriho
NZ207842A (en) 1983-04-25 1988-02-12 Chiron Corp Production of human insulin-like growth factor (igf) using cdna
US5010182A (en) * 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
EP0548267A4 (en) * 1990-09-04 1994-11-23 Salk Inst Biotech Ind Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
ATE177472T1 (de) * 1990-09-14 1999-03-15 Chiron Corp Expression von makrophagen-induzierbaren proteinen (mips) in hefezellen
ATE158816T1 (de) 1990-11-26 1997-10-15 Genetics Inst Expression von pace in wirtszellen und verfahren zu dessen verwendung
DK300090D0 (da) * 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
ATE220105T1 (de) * 1991-04-01 2002-07-15 Merck & Co Inc Gene, die die proteolytische aktivitaet von pichia beeinflussen und deren verwendung
US6348327B1 (en) 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
DK0682710T3 (da) * 1993-02-10 2004-03-01 Unilever Nv Isolationsmetode, ved hvilken der anvendes immobiliserede proteiner med specifikke kapaciteter
US5538863A (en) * 1993-07-01 1996-07-23 Immunex Corporation Expression system comprising mutant yeast strain and expression vector encoding synthetic signal peptide
US6451562B1 (en) 1993-12-22 2002-09-17 Human Genome Sciences, Inc. Polypeptides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) polynucleotides
US6495129B1 (en) 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
US5629167A (en) 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
RU2167939C2 (ru) * 1994-06-16 2001-05-27 Ново Нордиск А/С Способ продуцирования полипептида в дрожжах
US5639642A (en) * 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
IL114160A (en) * 1994-06-17 2006-12-31 Novo Nordisk As Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast
HRP940432B1 (en) * 1994-08-05 2003-10-31 Pliva Pharm & Chem Works Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin
EP0779927A1 (en) * 1994-09-08 1997-06-25 Chiron Corporation A method of improved production of insulin-like growth factor
GB9513967D0 (en) * 1995-07-08 1995-09-06 Univ Leicester Insulin
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
AU733007B2 (en) * 1996-09-24 2001-05-03 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
AU4977697A (en) 1996-09-25 1998-04-17 Vanderbilt University Genetically engineered yeast with modified signal peptidase complex
EP1935901A1 (en) * 1996-12-13 2008-06-25 Novartis Vaccines and Diagnostics, Inc. Analysis and separation of platelet-derived growth factor proteins
KR100381494B1 (ko) * 1997-06-30 2003-07-22 바이오 테크놀로지 제네랄 코오포레이션 인간인슐린의제조방법
US6068993A (en) * 1997-07-02 2000-05-30 Biobras Sa Vector for expression of heterologous protein and methods for extracting recombinant protein and for purifying isolated recombinant insulin
JP2001512684A (ja) 1997-08-05 2001-08-28 カイロン コーポレイション 新規のｐｉｃｈｉａｐａｓｔｏｒｉｓ遺伝子配列およびそれらの使用方法
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
EP1047784B2 (en) 1998-01-14 2015-03-18 Novartis Vaccines and Diagnostics S.r.l. Neissera meningitidis antigens
AU2149899A (en) * 1998-01-23 1999-08-09 Novo Nordisk A/S Process for making desired polypeptides in yeast
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP2261338A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
AU5504999A (en) * 1998-07-20 2000-02-14 Frenken, Leon Gerardus Joseph Production of proteins
DE69932247T2 (de) 1998-08-21 2007-05-31 Immunex Corp., Thousand Oaks Menschliches il-1 epsilon dna und polypeptide
WO2000066741A2 (en) 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
JP2004508801A (ja) 1999-10-29 2004-03-25 カイロン　ソチエタ　ア　レスポンサビリタ　リミタータ ナイセリア抗原性ペプチド
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
DE60120372T2 (de) 2000-03-24 2007-07-05 Genentech Inc., San Francisco Verwendung von insulin zur behandlung von knorpelkrankheiten
US6605450B1 (en) 2000-05-25 2003-08-12 Chiron Corporation Iron regulation of the PpSEC10 transcriptional regulatory region of Pichia pastoris and methods of use
US7132273B1 (en) 2000-07-26 2006-11-07 Korea Research Institute Of Bioscience And Biotechnology Cell wall anchor proteins derived from yeast, genes thereof and cell surface expression systems using the same
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
KR101054735B1 (ko) * 2001-07-06 2011-08-05 잇판자이단호진 가가쿠오요비겟세이료호겐쿠쇼 유전자 재조합 에카린 및 그를 제조하는 방법
RU2331435C2 (ru) 2001-12-12 2008-08-20 Чирон Срл. Иммунизация против chlamydia trachomatis
AU2003243316A1 (en) * 2002-05-24 2003-12-12 Nps Allelix Corp. Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
DK1521767T3 (da) * 2002-05-24 2010-04-12 Medtronic Inc Fremgangsmåder og konstrukter til ekspression af clostripain med højt udbytte
WO2004024885A2 (en) 2002-09-13 2004-03-25 Cornell Research Foundation, Inc. Using mutations to improve aspergillus phytases
EP1562982B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unexpected surface proteins in neisseria meningitidis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
EP2133362B1 (en) 2003-07-25 2012-04-18 Amgen, Inc Methods relating to LDCAM and CRTAM
HRP20120315T1 (hr) * 2003-11-21 2012-05-31 Nps Pharmaceuticals Proizvodnja peptida 2 nalik glukagonu i analoga
WO2005055944A2 (en) 2003-12-05 2005-06-23 Cincinnati Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US7632924B2 (en) * 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
WO2006091231A2 (en) * 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
CN103520735B (zh) * 2004-12-22 2015-11-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
EP2399893B1 (en) 2004-12-22 2018-08-15 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP1836316A4 (en) 2004-12-22 2009-07-22 Ambrx Inc PROCESS FOR EXPRESSION AND CLEANING OF RECOMBINANT HUMAN GROWTH HORMONE
EP1836298B1 (en) * 2004-12-22 2012-01-18 Ambrx, Inc. COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
WO2006132925A2 (en) 2005-06-01 2006-12-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy
AU2006255122B2 (en) * 2005-06-03 2010-10-21 Ambrx, Inc. Improved human interferon molecules and their uses
AU2005335491B2 (en) 2005-08-18 2010-11-25 Ambrx, Inc. Compositions of tRNA and uses thereof
CN101400646A (zh) * 2005-11-08 2009-04-01 Ambrx公司 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
DK2339014T3 (en) 2005-11-16 2015-07-20 Ambrx Inc Methods and compositions comprising non-natural amino acids
WO2007070659A2 (en) * 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
CN106008699A (zh) * 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
JP5399906B2 (ja) * 2006-09-08 2014-01-29 アンブルックス，インコーポレイテッド 脊椎動物細胞用のハイブリッドサプレッサーｔｒｎａ
EP2064333B1 (en) * 2006-09-08 2014-02-26 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
WO2008032659A1 (fr) * 2006-09-14 2008-03-20 National Institute Of Advanced Industrial Science And Technology Peptide signal de sécrétion doté d'une efficacité améliorée, et procédé de production de protéine au moyen dudit peptide
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
MX344166B (es) 2008-02-08 2016-12-07 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
CN102159230A (zh) 2008-07-23 2011-08-17 Ambrx公司 经修饰的牛g-csf多肽和其用途
AU2009296267B2 (en) 2008-09-26 2013-10-31 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
BR122012024318A2 (pt) 2008-09-26 2019-07-30 Ambrx, Inc. Polipeptídeos modificados de eritropoetina animal e seus usos
EP2258855A1 (en) 2009-05-28 2010-12-08 Universität für Bodenkultur Wien Expression sequences
EP2494050A4 (en) * 2009-10-30 2013-10-30 Merck Sharp & Dohme GRANULOCYTIC COLONY STIMULATING FACTOR MADE IN GLYCOENGINEERED PICHIA PASTORIS
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
BR112012015597A2 (pt) 2009-12-21 2017-01-31 Ambrx Inc peptídeos de somatotropina suínos modificados e seus usos
EA030886B1 (ru) 2010-08-17 2018-10-31 Амбркс, Инк. Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
KR102079293B1 (ko) 2012-10-29 2020-02-19 론자 리미티드 발현 서열
EP2999712B1 (en) 2013-04-30 2018-11-21 Donald Danforth Plant Science Center Antifungal plant proteins, peptides, and methods of use
WO2015128507A1 (en) 2014-02-28 2015-09-03 Novo Nordisk A/S Mating factor alpha pro-peptide variants
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
CN111094572B (zh) * 2018-02-09 2023-04-04 江苏恒瑞医药股份有限公司 一种密码子优化的人胰岛素类似物前体基因和信号肽基因
US20210388037A1 (en) 2018-11-19 2021-12-16 Basf Se Leader sequence for yeast
CN110028562B (zh) * 2019-04-25 2023-03-03 福州量衍科技有限公司 优化的Komagataella pastoris酵母α-factor信号肽及应用
US12331302B2 (en) 2019-11-08 2025-06-17 The Regents Of The University Of California Fungal autoinducible expression system
BR102019026867A2 (pt) * 2019-12-16 2021-06-29 Petróleo Brasileiro S.A. - Petrobras Microrganismos geneticamente modificados que realizam a produção heteróloga de versões modificadas da proteína surfactante lv-ranaspumina-1 (lv-rsn-1), as versões modificadas dessa proteína surfactante, os genes sintéticos que codificam essa proteína surfactante, os cassetes de expressão contendo esses genes sintéticos, e os vetores de expressão contendo esses genes sintéticos
WO2026009000A1 (en) 2024-07-04 2026-01-08 Solasta Bio Limited Methods for production of insecticidal neuropeptides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
IL63270A0 (en) 1980-08-05 1981-10-30 Univ Leland Stanford Junior Eukaryotic autonomously replicating segment
US4775622A (en) * 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
EP0116201B1 (en) 1983-01-12 1992-04-22 Chiron Corporation Secretory expression in eukaryotes
CA1341302C (en) 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
JPS60501140A (ja) * 1983-04-22 1985-07-25 アムジエン 酵母による外因性ポリペプチドの分泌
US4546083A (en) 1983-04-22 1985-10-08 Stolle Research & Development Corporation Method and device for cell culture growth
NZ207926A (en) * 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
NZ207842A (en) * 1983-04-25 1988-02-12 Chiron Corp Production of human insulin-like growth factor (igf) using cdna
US4870008A (en) * 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
ATE102250T1 (de) 1984-05-11 1994-03-15 Chiron Corp Erhoehte hefetranskription unter verwendung einer hybridkonstruktion der promotorregion.
JPS6156078A (ja) * 1984-07-27 1986-03-20 Suntory Ltd 酵母を宿主とする分泌発現ベクタ−
WO1986001515A1 (en) * 1984-08-29 1986-03-13 Chiron Corporation Expression of human connective tissue activator and related peptides
DK129385A (da) * 1985-03-22 1986-09-23 Novo Industri As Peptider og fremstilling deraf
JPS6236183A (ja) 1985-06-20 1987-02-17 ザ・サルク・インステイチユ−ト・バイオテクノロジ−／インダストリアル・アソシエイツ・インコ−ポレ−テツド サツカロミセス・セレビシエからのポリペプチドの発現および分泌
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
EP0387319B1 (en) * 1988-07-23 1996-03-06 Delta Biotechnology Limited Secretory leader sequences

Also Published As

Publication number Publication date
NO178829B (no) 1996-03-04
DK728588A (da) 1989-07-01
DK200500130A (da) 2005-01-27
HK139994A (en) 1994-12-16
DE3885728D1 (de) 1993-12-23
PT89367A (pt) 1989-12-29
EP0324274B1 (en) 1993-11-18
AU2765088A (en) 1989-07-06
FI886008L (fi) 1989-07-01
CA1340772C (en) 1999-09-28
EP0324274A1 (en) 1989-07-19
NO885786D0 (no) 1988-12-28
NO885786L (no) 1989-07-03
IE62087B1 (en) 1994-12-14
JPH022339A (ja) 1990-01-08
IL88802A0 (en) 1989-07-31
ATE97441T1 (de) 1993-12-15
AU616228B2 (en) 1991-10-24
FI100995B (fi) 1998-03-31
US5602034A (en) 1997-02-11
USRE37343E1 (en) 2001-08-28
PT89367B (pt) 1993-09-30
DK728588D0 (da) 1988-12-29
NO178829C (no) 1996-06-12
DE3885728T2 (de) 1994-03-10
IE883896L (en) 1989-06-30
DK175910B1 (da) 2005-06-13
JP2793215B2 (ja) 1998-09-03
DK176075B1 (da) 2006-04-10

Similar Documents

Publication Publication Date Title
ES2059547T3 (es) Expresion y secrecion mejoradas de proteinas heterologas en levadura, empleando secuencia conductora de factor alfa truncado.
ES2056817T3 (es) Transformacion de trichoderma.
DE3853384D1 (de) Peptid.
ES2131069T3 (es) Expresion de proteinas recombinantes en bacterias atenuadas.
DE69227462D1 (de) Peptide mit wachstumshormonfreisetzender aktivität
ES2077666T3 (es) Proteina de union a fibronectina y su preparacion.
ES2062514T3 (es) Sistema de procesamiento de levadura que comprende un aminoacido cargado negativamente adyacente al sitio de procesamiento.
NO965362L (no) Syntetiske lederpeptidsekvenser
ES8402351A1 (es) Procedimiento para producir interferon inmune humano.
YU79393A (sh) Terapeutska kombinacija
ES2073571T3 (es) Aplicacion de nuevos fragmentos de adn como secuencia que codifica un peptido señal para la secrecion de proteinas maduras, mediante levaduras recombinantes, cassettes de expresion, levaduras transformadas y procedimiento correspondiente de preparacion de proteinas.
DE3586206D1 (de) Metoprololsuccinat und dieses enthaltende pharmazeutische zusammensetzung.
DE3586313D1 (de) Konjugate von pharmazeutisch nuetzlichen proteinen.
ATE110743T1 (de) Antikoagulierende peptide.
DE3685626D1 (de) Sequenzierung von peptiden.
DK0669979T3 (da) C-C CKR-1, kemokinreceptor
ATE81135T1 (de) Aktive thymopentin-analoga.
ES2052791T3 (es) Nuevos peptidos señal capaces de funcionar en levaduras, y expresion secretora de proteinas heterologas que utilizan los mismos.
ATE125269T1 (de) Radiomarkierte peptide mit antikoagulanswirkung.
ES2054353T3 (es) Expresion de las alipoproteinas humanas ai-milano en levadura.
ES2080800T3 (es) Polipeptidos y analogos de polipeptidos con actividad inhibitoria frente a la elastasa humana.
ES2052583T3 (es) Derivados de peptidos relacionados con el gel calcitonina.
DK0707473T3 (da) Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler
ES2100960T3 (es) Estructura proteica de la toxina vegetal gelonina.
ES2056753A6 (es) Un procedimiento para la produccion de un polipeptido que tiene actividad de factor quemotactico de monocitos humanos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 324274

Country of ref document: ES